HOME > LATEST

LATEST

BUSINESS Enhertu Combo Accepted for US Review in First-Line HER2 Breast Cancer

September 25, 2025
BUSINESS Chugai Seeks Avastin Label Expansion for Neurofibromatosis Type 2

September 25, 2025
REGULATORY LDP Leadership Race Underway, Healthcare-Savvy Lawmakers Among Endorsers

September 24, 2025
BUSINESS Mochida and Itochu to Each Take 20% Stake in And Pharma

September 24, 2025
REGULATORY FPMAJ Calls for Scrapping Huge-Seller, Spillover Re-Pricing at Public-Private WG Hearing

September 24, 2025
BUSINESS PharmaEssentia Files for ET Indication of Besremi in Japan

September 24, 2025
BUSINESS FDA Turns Down Otsuka’s PTSD Bid for Rexulti

September 24, 2025
BUSINESS Moderna Rolls Out LP.8.1-Tailored Spikevax in Japan

September 24, 2025
BUSINESS Nikon Bets 10 Billion Yen on Regenerative Medicine CDMO Push

September 22, 2025
REGULATORY Japan OKs Biosimilars of Eylea, Actemra, Simponi, Ranmark in Likely First Debut

September 22, 2025
ORGANIZATION JPMA Publishes TPP Overview to Bridge Academia and Industry: R&D Chair

September 22, 2025
BUSINESS Daiichi Sankyo’s ADC I-DXd Shows Distinct Safety Profile in SCLC: R&D Head

September 22, 2025
REGULATORY MHLW Panel Endorses Rx-to-OTC Switch of Tadalafil in Japan

September 22, 2025
BUSINESS Allergan Seeks Label Expansion for Botox Vista in Japan

September 22, 2025
BUSINESS Takeda to Ship Medicines via Wind-Powered Vessel from 2026

September 22, 2025
REGULATORY Japan Approves Pluvicto, Izervay, and Lots More; Subcutaneous Rybrevant Not on Roster

September 22, 2025
REGULATORY Amitiza, Shingrix under PMDA Safety Review

September 22, 2025
REGULATORY Japan Extends Re-Examination Period for Nurtec, Dormicum

September 22, 2025
REGULATORY Takaichi Highlights Drug Discovery as Crucial Growth Field in LDP Race

September 22, 2025
BUSINESS Nippon Shinyaku’s DMD Med Bags Orphan Status in US

September 22, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…